HBSHS A.I CyberSecurity Scoring
23/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Hologic Breast & Skeletal Health Solutions in 2026.
No incidents recorded for Hologic Breast & Skeletal Health Solutions in 2026.
No incidents recorded for Hologic Breast & Skeletal Health Solutions in 2026.
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love to innovate and develop exciting technologies, and we offer competitive salaries and progressive benefits. But it’s our culture - of Care, Collaboration and Courage - that really sets us apart. Through a spirit of ownership and can-do attitude, we work together to win.. We’re a company of people who care about each other, about our customers and their patients, and about our communities. Together, we fulfill our shared purpose of Life Unlimited. Please note: not all products referred to may be approved for use or available in all markets.
We are dedicated to transforming lives by improving the journey to a healthy, beautiful smile. Discover your straight path to a bright future at Align Technology. As a part of our smart, diverse and fast-moving global team, you'll make an impact on the market leader that's moving an industry forward. Want to find out what's next for us—and for you? Follow us on LinkedIn for business updates and check out our current opportunities at www.aligntech.com/careers. 25 years ago, we pioneered the market for clear aligners. Since then, we have continuously innovated with new products and technologies that revolutionize treatments for doctors and their patients. Today, doctors and labs in over 100 markets use the Invisalign system, iTero intraoral scanners and exocad software to improve smiles for patients – from simple tooth alignment to complex corrections, kids to adults, orthodontics to multi-disciplinary restorative treatment. Learn more about Align Technology and our products: www.aligntech.com www.invisalign.com www.itero.com www.exocad.com
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We advance our mission to alleviate pain and improve the quality of life for patients around the world with our innovative products and suite of integrated digital and robotic technologies leverage data, data analytics and artificial intelligence. Founded in 1927 and based in Warsaw, Zimmer Biomet has operations in more than 25 countries and sales in more than 100 countries. We maintain world-class scientific facilities and resources and collaborate with leading clinicians and researchers around the world. Awards and Recognitions • Forbes: America's Best Companies 2026 • Workhuman: Luminary Award 2025 & Innovator Award 2024 • TIME: America's Best Companies [Mid-Size] 2024 • Great Place to Work - Best Workplaces: Switzerland & Poland 2025 • Great Place to Work Certified 2025 - 2026: USA, Poland, India, Colombia, Ireland, Puerto Rico, Kingdom of Saudi Arabia, Switzerland • MedTech: Breakthrough Award Best New Technology Solution in Orthopedics 2025 • Top Employers Institute: China 2025 • VETS Indexes: 4 Star Employer 2025
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2024 Sales: $22.6 billion ● Industry: Medical Instruments & Supplies ● Employees: 53,000 worldwide ● 44+ Manufacturing and R&D Locations Worldwide ● $1.5 billion spent on research and development in 2024 ● ~14,200 patents owned globally in 2024 ● Products sold in ~75 countries ● Fortune 500 Company ● 9 consecutive years as one a World's Best Workplace Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com. See community guidelines here: https://tinyurl.com/yunjmzkx.
Olympus is passionate about creating customer-driven solutions for the medical industry. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 31,000 employees worldwide in nearly 40 countries and regions.
As a leading medical technology company, B. Braun protects and improves the health of people around the world. For more than 185 years, the family-owned company has been accelerating progress in health care with pioneering spirit and groundbreaking contributions. This innovative strength continues to be the foundation of B. Braun's success today—always with the goal of improving clinical outcomes, cost of care and patient benefits. More than 64,000 employees live Sharing Expertise worldwide, they make B. Braun a true partner that develops integrated solutions and sets new standards. By linking products, services and consulting, the company improves treatment processes and supports medical staff. In doing so, B. Braun always acts with future generations in mind, which is why responsibility for sustainable growth is embedded into all business processes. In 2024, the B. Braun Group generated sales of € 9.1 billion. Imprint: https://www.bbraun.com/en/imprint.html Privacy Policy: https://www.bbraun.com/en/privacy-policy.html
A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory’s role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what’s now to what’s next. We do this by accelerating care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Headquartered in Brea, Calif., Beckman Coulter Diagnostics has more than 11,000 global team members. Beckman Coulter is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health.
Latest updates, reports, and threat intel affecting the global network.
Hologic has released the fifth edition of its Global Women's Health Index, which it developed in partnership with Gallup.
Hologic HOLX has built a resilient Breast Health business, with its mammography products holding a leading market share. The division struggled this year,...
Investors have filed a class action lawsuit to block two private equity firms' plans to acquire breast imaging vendor Hologic for $18.3...
Hologic issues safety alert for breast biopsy needles ... Hologic sign RSNA 2024,. The safety notice was issued due to the risk of pieces of the...
In late December, the medical technology company sent customers a field safety notice for all lots of its Brevera Breast Biopsy System...
Hologic recalls breast biopsy needles ... Hologic has initiated a recall of all lots of the disposable 9-gauge needles used in its Brevera Breast...
Hologic has always thrived on innovations. The FDA-approved, 3DQuorum Imaging Technology was the first of several products powered by the...
Hologic closed at $74.50 in a shortened Christmas Eve session, with after-hours trading lifting the stock to $74.80 by 7:00 p.m. ET.
The latest data come just shy of a month after Hologic released a pair of separate studies supporting its mammography AI. Those studies found...
Craft CMS is a content management system (CMS). In versions 5.0.0-RC1 through 5.9.22 and 4.0.0-RC1 through 4.17.15, an attacker with only a GitHub account can plant a JavaScript payload in a craftcms/cms issue title. When a Craft admin uses the CraftSupport widget’s "Give feedback" screen and types a search term that returns the poisoned issue, the payload executes in the admin’s control panel session. No control panel account or elevated privileges are required on the attacker’s side. This issue has been fixed in versions 4.17.16 and 5.9.23.
Craft CMS is a content management system (CMS). In versions 5.0.0-RC1 through 5.9.21 and 4.0.0-RC1 through 4.17.14, theAssetsController::actionDeleteFolder() only requires the deleteAssets:<volume-uid> permission for the target folder. It never enforces deletePeerAssets:<volume-uid>, even though Assets::deleteFoldersByIds() cascades deletion to every descendant folder and every asset inside, regardless of the uploader's assigned privileges. A low-privilege user who has been granted folder-management rights on a shared volume can therefore destroy assets uploaded by other users (peer assets), bypassing the per-asset peer-permission check that the sibling actionDeleteAsset endpoint correctly applies. This issue has been fixed in versions 4.17.15 and 5.9.22.
Craft CMS is a content management system (CMS). Versions 5.0.0-RC1 through 5.9.20, and 4.0.0-RC1 through 4.17.13 contain an authorization issue in the AssetsController::actionReplaceFile that can delete a source asset without source delete permission by supplying both assetId and sourceAssetId. AssetsController::actionReplaceFile() supports replacing a target asset file using another existing asset as the source. The action loads: assetId -> $assetToReplace and sourceAssetId -> $sourceAsset, then enforces replace permissions using ($assetToReplace ?: $sourceAsset). When both IDs are provided, this expression resolves to the target asset so no permission check is performed against the source asset volume. When both assets are present, Craft copies the source file into the target and then deletes the source asset. There is no deletion check for for the source asset. An authenticated user who can replace files in one volume can delete assets in another volume where they do not have delete permission, as long as they can obtain a sourceAssetId, leading to broken content references and data loss. This issue has been fixed in versions 4.17.14 and 5.9.21.
Description: To issue and renew TLS certificates on behalf of customers, Cloudflare's Universal SSL feature automatically manages the CAA RRset for the customer's zone. This auto-managed RRset is permissive by design (e.g. 'issue "letsencrypt.org"' without parameters). On Universal SSL zones, Cloudflare's authoritative DNS serves this auto-managed RRset at query time, superseding any customer-configured CAA records on the zone. When a customer publishes a stricter CAA record using the RFC 8657 accounturi or validationmethods parameters, the Certificate Authority does not observe those parameters when evaluating the served RRset under RFC 8659. As a result, the RFC 8657 account-binding and validation-method-binding protections are not enforced end-to-end on Universal SSL zones. Successful exploitation could result in issuance of a browser-trusted TLS certificate to an attacker, enabling MITM against the affected domain. Exploitation is non-trivial in practice: an attacker would need to hold an ACME account at one of the Certificate Authorities in the served CAA RRset and to simultaneously satisfy domain control validation across the multiple geographically distinct Network Perspectives the CA relies on for Multi-Perspective Issuance Corroboration. Cloudflare prefixes are anycast-announced from hundreds of locations globally, raising the bar against single-vantage-point BGP hijacks. Any resulting misissuance of a browser-trusted certificate is subject to Certificate Transparency logging required by major browsers, and would be visible to CT monitoring. Mitigation: Customers requiring strict RFC 8657 enforcement need to disable Universal SSL on the affected zone. Universal SSL's automatic CAA management and customer-set RFC 8657 accounturi and validationmethods enforcement are mutually exclusive by the nature of the issue, so there is no in-product workaround that preserves both. Certificate Transparency monitoring is recommended for all customers as a general detection control. Credits: David Osipov (ORCID: https://orcid.org/0009-0005-2713-9242), independent researcher
Out of bounds read and write in Tint in Google Chrome prior to 150.0.7871.46 allowed a remote attacker to potentially perform out of bounds memory access via a crafted HTML page. (Chromium security severity: High)
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.